乳糖醇联合[具体物质1]和[具体物质2]根除产OXA-48肠道菌的概念验证试验
Proof-of-concept trial of the combination of lactitol with and for the eradication of intestinal OXA-48-producing .
作者信息
Ramos-Ramos Juan Carlos, Lázaro-Perona Fernando, Arribas José Ramón, García-Rodríguez Julio, Mingorance Jesús, Ruiz-Carrascoso Guillermo, Borobia Alberto M, Paño-Pardo José Ramón, Herruzo Rafael, Arnalich Francisco
机构信息
1Unidad de Microbiología Clínica y Enfermedades Infecciosas, Servicio de Medicina Interna, Hospital Universitario La Paz, Paseo de La Castellana 261, 28046 Madrid, Spain.
2Servicio de Microbiología, Hospital Universitario La Paz, IdiPaz, Paseo de La Castellana 261, 28046 Madrid, Spain.
出版信息
Gut Pathog. 2020 Apr 7;12:15. doi: 10.1186/s13099-020-00354-9. eCollection 2020.
BACKGROUND
The major reservoir of carbapenemase-producing (CPE) is the gastrointestinal tract of colonized patients. Colonization is silent and may last for months, but the risk of infection by CPE in colonized patients is significant.
METHODS
Eight long-term intestinal carriers of OXA-48-producing (OXA-PE) were treated during 3 weeks with daily oral lactitol (Emportal), and (Infloran). Weekly stool samples were collected during the treatment period and 6 weeks later. The presence of OXA-PE was investigated by microbiological cultures and qPCR.
RESULTS
At the end of treatment (EoT, secondary endpoint 1), four of the subjects had negative OXA-PE cultures. Three weeks later (secondary endpoint 2), six subjects were negative. Six weeks after the EoT (primary endpoint), three subjects had negative OXA-PE cultures. The relative intestinal load of OXA-PE decreased in all the patients during treatment.
CONCLUSIONS
The combination of prebiotics and probiotics was well tolerated. A rapid reduction on the OXA-PE intestinal loads was observed. At the EoT, decolonization was achieved in three patients. NCT02307383. EudraCT Number: 2014-000449-65.
背景
产碳青霉烯酶（CPE）的主要储存库是定植患者的胃肠道。定植是无症状的，可能持续数月，但定植患者感染CPE的风险很大。
方法
8名产OXA-48（OXA-PE）的长期肠道携带者接受了为期3周的每日口服乳糖醇（恩波他尔）和（英福兰）治疗。在治疗期间和6周后每周收集粪便样本。通过微生物培养和qPCR检测OXA-PE的存在。
结果
治疗结束时（EoT，次要终点1），4名受试者的OXA-PE培养结果为阴性。3周后（次要终点2），6名受试者为阴性。EoT后6周（主要终点），3名受试者的OXA-PE培养结果为阴性。治疗期间所有患者的OXA-PE相对肠道负荷均下降。
结论
益生元和益生菌的联合耐受性良好。观察到OXA-PE肠道负荷迅速降低。在EoT时，3名患者实现了去定植。NCT02307383。欧盟临床试验编号：2014-000449-65。
Zotero 插件